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Most G protein-coupled receptors (GPCRs) started as orphan GPCRs. Matching them to known neuromodu-
lators led to the elucidation of the broad diversity of the neuroreceptor families. Moreover, orphan GPCRs
have also been used as targets to discover novel neuromodulators. These discoveries have had profound
impact on our understanding of brain function. Here, I present an overview of how some of the novel neuro-
peptides have enlarged our comprehension of responses that direct sleep/wakefulness, the onset of obesity
and the feeding response. I also discuss other advances gained from orphan GPCR studies such as the
concept of specificity in neuromodulation or of receptors acting as sensors instead of synaptic transmitters.
Finally, I suggest that the recently discovered neuromodulators may hold the keys to our understanding of
higher brain functions and psychiatric disorders.Synaptic transmission is viewed as depending primarily on the
actions of glutamate and y-aminobutyric acid (GABA), and the
majority of CNS interneuronal interactions monitored electro-
physiologically are driven by these two neurotransmitters. A
few other neurotransmitters, such as acetylcholine, serotonin,
or ATP also elicit electrophysiological responses. Together,
these responses constitute the trunk of synaptic transmission.
The role of the branches is carried out by neuromodulators.
Neuromodulators can be classified as transmitters that, like
glutamate and GABA, are released from a neuron and interact
with specific receptors found on the membrane of a recipient
neuron (Figure 1). Contrary to glutamate or GABA, they do not
interact with ligand-gated ion channels but with G protein-
coupled receptors (GPCRs). Activation of these GPCRs induces
second messenger response(s) that changes the biochemical
properties of the recipient cell and consequently can modulate
its electrophysiological responsiveness but also its transcrip-
tional activity or its metabolism. Note that glutamate, GABA
and the neurotransmitters mentioned above activate their own
GPCRs, they therefore can also act as neuromodulators.
Because only a limited number of second messenger pathways
exist, it is the neuromodulator-receptor interaction that needs to
provide the complexity required for brain function. However,
because this interaction is based on a binary mechanism,
complexity must rely on the diversity of the neuromodulators
and their receptors.
The Neuromodulators and Their Receptors
The search for neuromodulators began indeedwith the discovery
of acetylcholine, although itwasdiscoveredasaneurotransmitter
according to theabovedefinition.Neuromodulatorswerediscov-
ered through their abilities to regulate physiological responses in
organ or tissue preparations (Langley and Magnus, 1905). This
search gained another dimension when peptides were found to
belong to this class of transmitters. Then lipid mediators and
other small molecules were found to act as neuromodulators.12 Neuron 76, October 4, 2012 ª2012 Elsevier Inc.In parallel, neuromodulator receptors were being defined by
pharmacological means. Synthetic ligands were being devel-
oped and used to differentiate these receptor identities. A few
receptors were even purified and their sequences determined.
This culminated with the discovery that the b2-adrenergic
receptor and the opsins share a seven transmembrane domains
topology (7TMs) and some sequence similarities (Dixon et al.,
1986). Since the sole link between these two receptors is the
fact that they induce G protein-mediated cellular responses,
this discovery suggested thatGPCRsmay belong to a supergene
family. This suggestion was reinforcedwith the cloning of the first
neuropeptide receptor (substance K receptor; Masu et al., 1987)
and opened the door to the search for GPCRs by homology
screening approaches such as low-stringency hybridization
and degenerate polymerase chain reaction (PCR) (Bunzow
et al., 1988; Libert et al., 1989).
The receptors cloned via these strategies are by definition
unmatched to natural ligands. They are ‘‘orphan’’ receptors.
But at that time, some 50 neuromodulators were known to exist
but had no cognate cloned receptors. The cloning of the orphan
GPCRs offered a solution to this problem. The approach was to
express orphan GPCRs in cells in culture and to use these heter-
ologous GPCRs as targets for matching to possible neuromodu-
lators. Insights in the orphan GPCR tissue expression profile as
well as random testing proved to be successful in matching
the first orphan GPCRs to known neuromodulators. The first
deorphanized GPCRs, the 5HT-1A, and the D2 dopamine
receptors were reported in 1988 (Bunzow et al., 1988; Fargin
et al., 1988). This strategy was rapidly espoused worldwide
and is now known as reverse pharmacology (Libert et al.,
1991; Mills and Duggan, 1994).
During the first part of the 90’s, application of the reverse phar-
macology strategy led to the molecular identification of many
GPCRs (Civelli et al., 2006). These DNA sequences allowed for
the determination of their definitive pharmacological profiles as
well as for in-depth analyses of their sites of expression. In
Figure 1. The Synaptic Transmission
The numbers of molecules or genes are
derived from the IUPHAR database (http://www.
iuphar-db.org/DATABASE). LGIC, ligand-gated
ion channel; GPCR, G protein-coupled receptors.
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sequentially related GPCRs and the blossoming of the GPCR
subfamilies. Most often, the cloning of the GPCR genes have
greatly extended the diversity of the subfamilies (Civelli et al.,
2006). These discoveries have had lasting impact in the fields
of pharmacological and pharmaceutical research.
Concomitantly, the overall number of orphan GPCRs was
steadily increasing due to the mining of the database of ex-
pressed sequence tagged cDNAs (Marchese et al., 1994;
O’Dowd et al., 1998). It became clear that the numbers of GPCRs
outnumbered the number of known neuromodulators (later the
completion of the human genome revealed the full extent of
the GPCR diversity). The conclusion of this recognition was
(and still is) that many orphan GPCRs must be activated by
undiscovered neuromodulators, since inactive GPCRs would
have been evolutionarily discarded. The corollary of this conclu-
sion was that orphan receptors may be used as baits to identify
novel neuromodulators (Civelli et al., 2001).
The Search for Novel Neuromodulators
The approach used to isolate novel neuromodulators consists of
expressing an orphan GPCR in heterologous cells and test these
against brain tissue extracts. Receptor reactivity is monitored by
quantifying changes in second messenger levels. The extract
displaying reactivity is fractionated and its purification is pursued
to homogeneity. The first orphan GPCR used in this approach
was ORL-1, an orphan GPCR sequentially related to the opioid
receptors (Henderson and McKnight, 1997). Its activation was
monitored by monitoring intracellular decreases in cAMP levels.
Its neuromodulator was extracted from brain tissues and shown
to be a neuropeptide, named orphanin FQ or nociceptin (OFQ/N)
(Meunier et al., 1995; Reinscheid et al., 1995). This neuropeptide
shares sequence similarities to the opioid peptides but also
precise differences that render it inactive at opioid receptors (Re-
inscheid et al., 1998).
This strategy has since been used to discover the following
neuropeptides (Figure 5): the two orexins (Oxs) (Sakurai et al.,
1998), also identified through an RNA subtraction approach as
hypocretins (Hcrts) (de Lecea et al., 1998); prolactin-releasing
peptide (PrRP) (Hinuma et al., 1998); apelin (Tatemoto et al.,
1998); ghrelin (Kojima et al., 1999); kisspeptin/metastin (OhtakiNeuron 7et al., 2001); the two prokineticins (Lin
et al., 2002; Masuda et al., 2002); neuro-
peptide B and neuropeptide W (NPB/W)
(Brezillon et al., 2003; Fujii et al., 2002;
Shimomura et al., 2002; Tanaka et al.,
2003); neuropeptide S (NPS) (Sato et al.,
2002; Xu et al., 2004); neuromedin S
(Mori et al., 2005); and finally relaxin-3
(Liu et al., 2003). Each of these neuropep-
tides has been the subject of intenseresearch, which has helped better understand a number of phys-
iological processes. I will not cover all the advances that they
have brought to neuroscience here, but in the next section, I
review, as examples, three of the brain-directed responses for
which our understanding has been drastically impacted by
orphan GPCR research.
Neuromodulatory Responses Directed by Orphan
GPCRs
Sleep/Wakefulness
Studies on one orphan GPCR system, the orexin/hypocretin
(Oxs/Hcrts) system, has had a great impact on our under-
standing sleep/wakefulness states. Soon after the discovery of
the Oxs/Hcrts it was shown that mice devoid of Oxs/Hcrts
exhibit a pronounced narcoleptic behavior (Chemelli et al.,
1999). This conclusion was paralleled by genetic studies of an
autosomal recessive mutation responsible for narcolepsy in
dogs, which showed that the responsible gene is a defective
Oxs/Hcrts receptor 2 (Lin et al., 1999), further confirmed by the
lack of Oxs/Hcrts in several individuals afflicted with narcolepsy
(Nishino et al., 2000).
The mode of action of Ox/Hcrt system on sleep an arousal has
been investigated (Figure 2). From the afferent side, it is known
that the preoptic area, especially the ventrolateral preoptic
nucleus (VLPO), plays a critical role in the initiation of nonrapid
eye movement (NREM) sleep and maintenance of both NREM
and rapid eye movement (REM) sleep (Sherin et al., 1998).
Neurons in the VLPO fire at a rapid rate during sleep and slow
down during the waking period. These neurons contain GABA
and/or galanin and promote sleep. GABAergic neurons origi-
nating in the preoptic area densely innervate Ox/Hcrt neurons
(Sakurai et al., 2005; Yoshida et al., 2006). The orexin neurons
are inhibited by activation of the GABA system (Xie et al., 2006;
Yamanaka et al., 2003). These observations therefore suggest
that VLPO neurons send GABAergic projections to orexin
neurons to turn off orexin neurons during sleep.
From the efferent side, it has been shown that Ox/Hcrt neurons
innervate wake promoting centers such as the noradrenergic
neurons of the locus coerulues (LC), the serotonergic neurons
of the dorsal raphe (DR) and the histaminergic neurons of the
tuberomammilary nucleus of the hypothalamus (TMN) (Saper6, October 4, 2012 ª2012 Elsevier Inc. 13
Figure 2. The Role of the Orexins/
Hypocretins in the Sleep/Wake Response
In blue: GABA and its inhibitory effect on mono-
aminergic centers. In red: the stimulatory effect of
the Oxs/Hcrts on the same centers which activa-
tion results in arousal and wake. BF, basal fore-
brain; VLPO, ventrolateral preoptic nucleus; TMN,
tuberomammilary nucleus; LDT/PPT, laterodorsal
tegmental nucleus/pedunculopontine nucleus:
LC, locus coeluleus: DR, dorsal raphe.
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synchronized and modulate sleep/wake states. They fire toni-
cally during the awake state, less during NREM sleep, and not
at all during REM sleep (Lee et al., 2005; Vanni-Mercier et al.,
1984). Ox/Hcrt neurons discharge during active waking and
virtually cease firing during sleep, including the NREM and
REM periods (Lee et al., 2005) and thus should exert an excit-
atory influence on the wake-active neurons and help them
sustain their activity. In addition, Ox/Hcrt neurons project to lat-
erodorsal tegmental nucleus/pedunculopontine nucleus (LDT/
PPT) cholinergic neurons and affect the activity of these neurons
in wakefulness and REM sleep. Finally, the Oxs/Hcrts neurons
project and excite the cholinergic neurons of the basal forebrain
(BF) , which also regulate arousal. All together these data point at
the Ox/Hcrt system as a central modulator for the maintenance
of wakefulness. When dysfunctional it is a primary cause of the
narcolepsy-catalepsy syndrome.
Onset of Puberty
At the onset of puberty, neurons in the medial preoptic area of
the hypothalamus initiate the pulsatile secretion of gonadotropin
releasing hormone (GnRH), which reaches the pituitary gland
where it stimulates the release of the gonadotopic hormones
luteinizing hormone (LH) and follicle-stimulating hormone
(FSH). These hormones in turn act on the gonads to stimulate
synthesis of the sex steroids, which are required for spermato-
genesis and oogenesis. The mechanism that initiates the pulsa-
tile secretion of GnRH at puberty was unknown.
Then studies on patients with idiopathic hypogonadotropic
hypogonadism (IHH) (de Roux et al., 2003; Marchese et al.,
1994; Seminara et al., 2003) found that mutations in a particular
orphan GPCR, GPR54, were responsible for the phenotype.
These mutations resulted in loss of function or putative reduc-
tions in the GPR54 signaling. IHH is a clinical condition charac-
terized by absence of pubertal sexual development and low
gonadotropin levels and sex steroids. The role that GPR54 plays
in initiating fertility has been confirmed in mice by the generation
of lines with disruptions of the GPR54 gene (Funes et al., 2003;
Kauffman et al., 2007; Lapatto et al., 2007; Messager et al.,
2005; Seminara et al., 2003).14 Neuron 76, October 4, 2012 ª2012 Elsevier Inc.The discovery of kisspeptin/metastin
as the neuropeptide that activates
GPR54 allowed in-depth studies of all
aspects of the system (Figure 3). First,
mice with a disrupted kisspeptin gene
display the similar reproductive defects
found in the GPR54 mutants (d’Angle-
mont de Tassigny et al., 2007; Lapattoet al., 2007). These mice exhibit IHH, have abnormal pubertal
maturation and low sex steroid levels but retain the ability to
secrete gonadotrophic hormones after kisspeptin injection.
Then, the expression patterns of GPR54 and kisspeptin in the
hypothalamus are also consistent with the function of these
genes in the control of reproduction. Kisspeptin and GPR54
are expressed in discrete nuclei of the hypothalamus. Kisspeptin
is expressed in the arcuate nucleus (ARC), anteroventral periven-
tricular nucleus (AVPV) and the periventricular nucleus, (Gottsch
et al., 2004; Irwig et al., 2004). GPR54 is localized in the preoptic
areas and anterior and lateral hypothalamus, the diagonal band
of Broca and the medial septum (Han et al., 2005; Irwig et al.,
2004). More importantly, practically all the GnRH neurons
express GPR54 (Chemelli et al., 1999; Han et al., 2005; Irwig
et al., 2004). Kisspeptin and GPR54 expression increase at
puberty in many species. These increases are confined to the
AVPV and the periventricular nucleus and are not seen in the
ARC.
The hypothalamus-pituitary-gonadal axis implies that the sex
steroids are part of feedback loops with the pituitary and the
hypothalamus to regulate gonadotropin production. Yet direct
action of estrogen on GnRH neurons is unlikely because they
do not express estrogen receptor alpha. Studies on the kisspep-
tin system indicate that the kisspeptin-expressing neurons are
the intermediaries that receive the signals from the sex steroids.
They have therefore a very important modulatory role in the HPG
axis and in particular direct the onset of puberty.
Food Intake and Energy Homeostasis
Orphan GPCRs have had an important impact on our
understanding of appetite regulation and energy homeostasis.
Ghrelin, the natural ligand of the GH-S receptor is produced in
the stomach and is the most potent known circulating
orexigen (Wiedmer et al., 2007). Intravenous injections of ghrelin
into human volunteers increased their food intake by 28%
(Wren et al., 2001). Elevated ghrelin has been linked to the
hyperphagia and obesity of individuals with the Prader-Willi
syndrome (Cummings et al., 2002). Ghrelin is a functional
antagonist of leptin, produced in adipose tissues, which acts
as a satiety signal (Friedman and Halaas, 1998). Humans
Figure 3. Kisspeptin and the Onset of Puberty
GnRH pulses produced at the onset of puberty by neurons of the preoptic area
of the hypothalamus (POA) are under the regulation of kisspeptin (Kiss)
secreted by the arcuate nucleus (ARC, negative feedback by sex steroids) and
the anteroventral periventricular nucleus (AVPV, positive feedback by
estrogen). GnRH acts on the pituitary to rpoduce LH/FSH which act on the
gonads to produce sex hormones which in turn regulate the pituitary and the
POA in feedbacks loops. In red, stimulatory, and in blue, inhibitory pathways.
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and respond dramatically to leptin administration (Friedman
and Halaas, 1998). Ghrelin and leptin are released in the
circulation and converge on one brain center, the hypothalamic
arcuate nucleus (ARC), which is more readily accessed by
blood-borne peptides, and there act on two populations of
neurons. The first population expresses two orexigenic pep-
tides, the melanocortin antagonist Agouti-related peptide
(AgRP) and Neuropeptide Y (NPY). The second population ex-
presses the pro-opiomelanocortin (POMC) precursor and the
peptide cocaine and amphetamine-related transcript (CART)
(Figure 4).
Ghrelin stimulates NPY/AgRP neurons and thus promote the
production and secretion of NPY and AgRP peptides (Kojimaand Kangawa, 2008; Mondal et al., 2005). Studies with NPY-
or AgRP-knockout mice confirm these results (Chen et al.,
2004). Note that there are also ghrelin receptors on vagal
sensory nerves which play a role in the feeding response (Date
et al., 2002). Leptin, on the other hand, stimulates POMC/
CART neurons and inhibits NPY/AgRP neurons. Leptin effects
on POMC are of importance since fasting decreases POMC
expression (Coll et al., 2004). POMC is cleaved to a-melano-
cyte-stimulating hormone (aMSH), which is considered the
predominant POMC-derived product controlling energy. aMSH
acts at melanocortin 3 and melanocortin 4 receptors (MC3R
and MC4R, first identified as orphan GPCRs; Cone, 2005). The
NPY/AgRP neurons project to many of the same brain areas
as POMC neurons. They secrete AgRP, which acts as an antag-
onist at MC3R and MC4R (Cone, 2005) such that one action of
the NPY/AgRP neurons is to counter the activity of POMC
neurons. They also secrete NPY, which acts at NPY receptors
(first identified as orphan GPCRs) to stimulate food intake (Clark
et al., 1984; Stanley and Leibowitz, 1984). When either AgRP or
NPY is administered chronically into the brain, body weight
increases (Morton et al., 2006; Ollmann et al., 1997; Zarjevski
et al., 1993).
Although the NPY and POMC neurons project throughout
the brain, two target areas are of particular importance to food
intake regulation. The first is the paraventricular nucleus (PVN)
which expresses both MC3R/MC4R and NPY receptors and
synthesize and secrete neuropeptides that have a net catabolic
action, such as CRH and oxytocin (Atasoy et al., 2012). The
second is the lateral hypothalamic area (LHA), the brain center
that lesion studies have identified as the center for feeding
initiation. The LHA receives direct inputs from the ARC and
contains neurons that synthesize and secrete prominently two
anabolic peptides, ligands of orphan GPCRs, melanin-concen-
trating hormone (MCH), and the orexins (Oxs/Hcrts). Administra-
tions of MCH (Qu et al., 1996) or orexins (Sakurai et al., 1998)
increase food intake and body weight gain. The interplay
between these opposing hypothalamic circuits is therefore
seen as a major regulator of food intake and consequently of
energy homeostasis.Figure 4. The Role of Ghrelin in the Control of Food
Intake
Ghrelin produced by the stomach activates NPY/Agrp
neurons and inhibit POMC (a-MSH) neurons in the arcuate
nucleus. Leptin produced by the fat cells does the oppo-
site. NPY/Agrp and POMC neurons project to several brain
nuclei in particular the lateral hypothalamus (LHA) and the
paraventricular nucleus where they convey orexigenic
(red) and anorexigenic (blue) signals. The orexins/hypo-
cretins and MCH in the LHA have been shown to stimulate
appetite.
Neuron 76, October 4, 2012 ª2012 Elsevier Inc. 15
Figure 5. The Neuropeptides Discovered as
Ligands of Orphan GPCRs and Some of
Their Structures
In blue are residues that are conserved in the
neuropeptide families.
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New Modifications in Neuropeptide Structure
The natural ligands of two orphan GPCRs, two neuropeptides,
stand out with regard to their structures (Figure 5). One is
neuropeptide B (NPB), which is brominated at its N terminus
(Trp1) (Tanaka et al., 2003). This represents the first evidence
of bromination in mammals. NPB is similar to NPW, which is
not brominated. Both act at two related GPCRs. Since
des-Bromo-NPB is equipotent to brominated NPB at activat-
ing its receptors yet, the biological significance of the bro-
mination event is unclear (Hondo et al., 2008; Tanaka et al.,
2003).
The other neuropeptide is ghrelin, the only neuropeptide thus
far that is modified by a fatty acid. It is n-octanoylated at serine
3 (Ser3) (Kojima et al., 1999). In contrary to NPB, this modifica-
tion is essential for its activity. In view of the role of ghrelin as an
orexigenic factor, as discussed above, its acylation has become
a subject of research in its own right. It was found that there
exists one enzyme, ghrelin O-acyltransferase (GOAT) that
attaches octanoate to proghrelin (Gutierrez et al., 2008; Yang
et al., 2008), which is then processed to ghrelin. GOAT’s activity
is specific to ghrelin since no other acyltransferases do it and is
only expressed in tissues that express ghrelin (Yang et al.,
2008). This indicates that nature evolved a specific post-trans-
lational system for regulating the activity of a single neuropep-16 Neuron 76, October 4, 2012 ª2012 Elsevier Inc.tide, which putatively adds to the physio-
logical importance of ghrelin and opens
a new way for developing ghrelin-related
therapies.
The Concept of Specificity in
Neuromodulation
Studies on orphan GPCRs have also
impacted our understanding of specificity
in neuromodulation. Receptors are ex-
pected to bind one or several closely
related neuromodulators. This is ex-
pected to result from evolutionary con-
strains that aim at specifying neuromodu-
lation. For example, the three opioid
receptors bind all the opioid peptides
and have evolved structures that ensure
that they do not bind the related neu-
romodulator OFQ/N (Meng et al., 1996;
Reinscheid et al., 1998). The catechol-
aminergic receptors are closely related
phylogenetically and are activated by
structurally related neuromodulators.
Yet, nordrenaline and dopamine direct
different neuromodulatory responses,
although it has been shown that adrena-line and noradrenaline can efficiently activate the dopamine D4
receptor in vitro (Lanau et al., 1997) and as does dopamine at
adrenergic receptors in brain slices (Cornil et al., 2002).
The studies on the ligands of the Mas-related GPCRs (Mrgprs
or sensory neuron-specific receptors, SNSRs) may revise our
understanding of specificity. This receptor family comprises
more than 50 orphan GPCRs in mice, many of which are ex-
pressed in specific subsets of nociceptive sensory neurons
(Dong et al., 2001; Lembo et al., 2002). This highly restricted
expression suggests that Mrgprs are likely to be involved in
somatosensation, including pain or itch. Variable numbers of
Mrgprs exist in human, rat, and mouse, making any attempt at
orthologous classification difficult (Zylka et al., 2003). One could
have expected that the Mrgprs, being part of a subfamily, would
bind similar transmitters. Ligands for a number of these recep-
tors have been identified (Bender et al., 2002; Lembo et al.,
2002; Robas et al., 2003; Shinohara et al., 2004). Many ligands
have been peptides, which contain the C-terminal RF/Y-G or
RF/Y-amide motif. Peptides bearing this motif, referred to as
RFamides, are known to possess antinociceptive properties
(Han et al., 2002; Tang et al., 1984; Yang et al., 1985). But other
Mrgprs have been found to be activated by adenine or cortista-
tin-14 or b-alanine, highlighting the lack of ligand specificity of
this receptor family (Bender et al., 2002; Lembo et al., 2002;
Robas et al., 2003; Shinohara et al., 2004).
Table 1. Orphan GPCRs and Neuromodulators
Therapeutic Indication Neuromodulator System
Schizophrenia MCH Activation increases apomorphine-induced PPI
Inhibition reverses PPI deficits in APO-SUS rats
Higher pMCH mRNA levels in APO-SUS rats
NPS Activation decreases MK-801-induced PPI
Activation decreases MK-801-induced vacuolization of the retrosplenial cortex
Kisspeptin Activation reverses PPI deficits in a model of schizophrenia
(maternal polyriboinosinic-polyribocytidylic acid (poly I:C) injection)
Anxiety OFQ/N Activation reduces anxiety responses
OFQ/N precursor KO mice exhibit anxiogenic behavior
NPS Activation reduces anxiety responses
Facilitates extinction of conditioned fear responses
NPB/W NPB/W Receptor 1 KO mice exhibit impaired contextual fear conditioning, impaired
safety conditioning, increased social interaction
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Constitutive activity may reflect a role for these receptors as
sensors more than as carriers of a specific neuromodulator
message. This could mean that Mrgprs evolved to recognize
more than one structural motif. This would be expected for
receptors signaling pleiotropic responses as is the case for the
human MrgprX1. This Mrgpr can respond to both the endoge-
nous peptide BAM8-22 at nanomolar concentrations and exog-
enous chloroquine at micromolar concentrations (Liu et al.,
2009). It has been shown that this Mrgpr is responsible for the
itching reaction associated with chloroquine administration.
Mice lacking a cluster of Mrg genes, including the Mrgprs orthol-
ogous to MrgprX1, display significant deficits in chloroquine-
induced itch, suggesting that one role for some of the Mrgprs
maybe to act as itch receptors (Liu et al., 2009).
The Neuromodulator Receptors that Act as Sensors
The concept that some GPCRs are not confined to transmitting
signals at the synapse but instead act as sensors has already
been shown for the calcium sensing receptor (Brown, 1999).
Indeed the largest family of orphan GPCRs, the olfactory
receptors, act as sensors. More recently, the orphan GPRC6A
has been first shown to be activated by not one but a series of
basic L-a-amino acids with a preference for basic amino acids
(Wellendorph et al., 2005; Pi et al., 2005) but also for androgen
and for osteocalcin (Pi et al., 2005). GPRC6A is therefore a
cation-, calcimimetic-, and osteocalcin-sensing receptor (Pi
and Quarles, 2012).
Other GPCRs may be sensing cell damage. For example the
orphan GPCRs, GPR91, and GPR99 have been shown to be
activated by succinate and a-ketoglutarate, respectively (He
et al., 2004). Succinate participates in the reabsorption of phos-
phate and glucose in the proximal tubules and stimulates gluco-
neogenesis (He et al., 2004). Succinate is however unable to
induce hypertension in GPR91-deficient mice thus demon-
strating that its activity relies on GPR91 activation. Succinate
belongs to the tricarboxylic acid cycle intermediates, which are
not expected to be secreted as neuromodulators, but which
will be released upon mechanical stress or cell death. Indeed,
it has been shown that succinate, acting through GPR91,governs retinal angiogenesis and show the propensity of retinal
ganglion neurons to act as sensors of ischemic stress (Sapieha
et al., 2008). It is therefore possible that several GPCRs aremoni-
toring cell death.
Perspective
Studies on orphan GPCRs have had a profound impact on our
understanding of neuromodulation. First the majority of the neu-
romodulator receptors, the GPCRs, started as orphan GPCRs,
and novel neuromodulators have been discovered as ligands
of orphan GPCRs. Novel neuromodulators have proven to be
the missing link in our understanding of biological function and
disorders, for example, the Oxs/Hcrts in narcolepsy and
kisspeptin in the initiation of puberty.
The neuromodulator GPCR family has undergone large expan-
sion during vertebrate evolution. A characteristic of many of the
neuromodulator receptor genes is their lack of introns. RNA-
based mechanisms, instead of classical gene duplications,
may have driven evolutionary events that are responsible for
the lack of introns (Fridmanis et al., 2007). This expansion
coincides with development of the so-called ‘‘higher’’ brain
functions. It is therefore not surprising that neuromodulation
has taken a prominent place in our understanding of behavior,
cognition, and affect. In this respect, neuromodulation offers
probably the highest hopes for our understanding the patho-
physiology of psychiatric disorders and indeed recent studies
emphasize this point (Table 1).
Schizophrenia
Schizophrenia has been, and still is, viewed as being, in signifi-
cant part, the result of one neuromodulator imbalance, dopa-
mine (Carlsson, 1988; Toda and Abi-Dargham, 2007). Other
newer neuromodulator systems, such as the metabotropic
glutamate system, are taking stand (Coyle, 2006; Stone et al.,
2007; Moghaddam and Javitt, 2012; Raedler et al., 2007) but
orphan GPCR systems may also play a role. The pathophysi-
ology of schizophrenia is difficult to study in animals. Possibly
our best bet is to record sensorimotor gating, the ability to selec-
tively allocate attention to a significant event by silencing the
background. Sensorimotor gating can be monitored by prepulseNeuron 76, October 4, 2012 ª2012 Elsevier Inc. 17
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produced by an intense stimulus (pulse) is suppressed when
a weak prestimulus (prepulse) immediately precedes it. Signifi-
cant PPI deficits have been observed in patients with schizo-
phrenia and other psychopathological disorders. Three orphan
GPCR systems have recently been shown to play a role in
regulating PPI (Cardon et al., 2010; Chung et al., 2011; Okamura
et al., 2010).
Neuropeptide S (NPS) is expressed in only a few brainstem
nuclei where it is coexpressed with glutamate. Dysfunctions in
glutamatergic neurotransmission via N-methyl-D-aspartate
(NMDA) receptors might be involved in the pathophysiology of
schizophrenia since a NMDA receptor antagonist, MK-801, has
been shown to induce psychotic-like behavior in humans and
animal models. MK-801 is further known to produce histological
changes such as cytoplasmic vacuoles in retrosplenial cortex
neurons where NPS receptors are highly expressed. It was
shown that NPS treatment attenuates MK-801-induced vacuoli-
zation in a dose-dependent manner. Furthermore, animals pre-
treated with NPS recover significantly from MK-801-induced
disruption of PPI. (Okamura et al., 2010).
The role of kisspeptin system has been investigated in a
neurodevelopmental animal model for schizophrenia (maternal
poly I:C treatment) in which abnormal PPI develops only at adult-
hood. In this system it was shown that kisspeptin expression is
related to the late onset of the schizophrenia-like behavior.
Furthermore, administrations of kisspeptin overcome the behav-
ioral deficits measured by PPI (Cardon et al., 2010).
Finally, the MCH system was also shown to affect schizo-
phrenia-like responses (Chung et al., 2011). MCH had been
shown to potentiate dopamine-induced cellular firing in the
shell of the nucleus accumbens (NAcSh), center of many dopa-
mine-directed responses and in particular of its role in sensori-
motor gating. As expected, administration of MCH to the
NAcSh potentiates apomorphine-induced PPI deficits without
affecting startle reactivity. This observation was extended by
using the APO-SUS and APO-UNSUS outbred rat model.
These animals have been selected and bred to exhibit differ-
ences in their susceptibility to apomorphine. The APO-SUS
rats have been described as an animal model displaying
aspects of schizophrenia. MCH was shown to disrupt PPI in
APO-UNSUS rats, but not in APO-SUS rats, in line with their
hyperdopaminergic activity of their mesolimbic dopamine
pathway, which may not be increased further upon exogenous
MCH injection. Moreover, blockade of the MCH system in
APO-SUS rats restores PPI deficits to levels similar to those
found in APO-SUS rats. Furthermore, this correlates with
pMCH mRNA levels, which were found increased in APO-
SUS versus APO-UNSUS rats. That there may be a link
between schizophrenia and the activity of the MCH system is
further suggested by a genomic linkage study, which revealed
significant associations between schizophrenia and a number
of SNPs and haplotypes located in the MCH receptor gene
locus (Chung et al., 2011).
Anxiety Disorders
Central administrations of OFQ/N exert anxiolytic effects
comparable to those resulting from classic anxiolytic drugs
treatment such as diazepam (Civelli, 2008). A synthetic OFQ/N18 Neuron 76, October 4, 2012 ª2012 Elsevier Inc.agonist induces anxiolytic-like effects in a variety of paradigms
such as the elevated plusmaze, pup isolation-induced ultrasonic
vocalization, fear-potentiated startle, Geller-Seifter conflict, and
conditioned lick suppression. Mice devoid of OFQ/N precursor
display signs of impaired stress adaptation and increased
anxiety-like behavior. OFQ/N knockout mice exhibit in-
creased stress-induced analgesia when housed in groups, an
environmental condition that may be a source of chronic mild
stress.
Central administrations of NPS also produce anxiolytic-like
effects independent of its effects on locomotion (Xu et al.,
2004). NPS furthermore facilitates extinction of conditioned
fear responseswhen administered into the amygdala, a response
that can be reversed by an NPS receptor antagonist (Ju¨ngling
et al., 2008). Consequently these data indicate that the NPS
system is involved not only in anxiety behavior and but also in
extinction. These results are in line with the observation that
specific NPSR alleles appear to be associated in human with
panic disorder, a specific form of anxiety disorder (Okamura
et al., 2007).
The role of the NPB/W system in fear conditioning has been re-
vealed by behavioral studies of the NPB/W receptor 1 KO mice
(Nagata-Kuroiwa et al., 2011). These mice exhibit an intriguing
pattern of behavioral abnormalities in the resident-intruder para-
digm. When presented with an intruder mouse, these mice
display impulsive contact with the strange mice, produce more
intense approaches and longer contact toward them. They
also sustain a higher elevation of heart rate and blood pressure
as compared to wild-type mice. Histological and electrophysio-
logical studies show that NPB/W receptor 1 acts as an inhibitory
regulator on a subpopulation of GABAergic neurons in the
lateral division of the central amygdala and terminates stress
responses. Together these data suggest that impairment of the
NPB/W system leads to stress vulnerability (Nagata-Kuroiwa
et al., 2011).
Concluding Remarks
The discussion of these five orphan GPCR systems provides
only a few examples of the data implicating novel neuromodu-
lators in the pathophysiology of neuropsychiatric disorders.
While these studies are still preliminary, they set new bases to
investigate brain function. Since there exist some 70 GPCRs
that are still orphan and that classify, on the basis of their
sequences, as potential neuromodulator receptors, many neu-
romodulators remain to be found which could drastically enrich
our understanding of mental health. In this respect, because
GPCRs are excellent targets for drug design, the newest
neuromodulator receptors carry our best hope for devising ther-
apies that aim at managing psychiatric disorders in a radically
new way.
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